I get some version of the same email every few months. Someone has been handed a project involving GHRH signaling, they’ve run into Tesamorelin in a paper or a supplier catalog, and they want the short version before committing to it. What is it? Why does it exist? And what are people actually doing with it at the bench?

So here’s my attempt to answer those questions once, in roughly the order people ask them. No usage advice, no hype. Just the molecule, the mechanism, the history, and the practical business of getting material you can trust.

What is it, in one sentence?

The tesamorelin peptide is a synthetic, 44-amino-acid analog of GHRH (1-44) carrying one deliberate change: a trans-3-hexenoyl group attached to the tyrosine at position 1.

That’s genuinely it. Same sequence as native GHRH, residue for residue, plus a small chemical cap on the front end. The molecular formula is C221H366N72O67S, and the molecular weight works out to about 5,136 Da.

If you mostly work with small molecules, that’s big. If you work with proteins, it’s tiny. It sits in a middle zone where synthesis is routine but not trivial, and where analytical chemistry does most of the quality work. Put simply, HPLC and mass spec are how you know what you’ve actually got.

Why add anything to the native hormone?

Because native GHRH barely survives long enough to matter.

The problem sits right at the N-terminus. GHRH starts Tyr1-Ala2, and that alanine in the second position is exactly what dipeptidyl peptidase-4 (DPP-4) is built to recognize. The enzyme clips off the first two residues, leaving a truncated fragment with much weaker activity at the receptor. In circulation this happens within minutes. For anyone trying to study a GHRH agonist over any useful time window, that’s a real headache.

The hexenoyl group fixes this in a tidy way. DPP-4 needs a free N-terminal amine to grab onto. Attach a six-carbon acyl chain to that amine and the enzyme loses its handle. The rest of the peptide is left alone.

The result is a reported half-life of roughly 26 to 38 minutes. That sounds modest. Half an hour? But it’s the difference between a molecule that’s mostly gone before anything measurable happens and one that sticks around long enough to produce a clean signal.

What I find elegant about it is the restraint. Plenty of analog programs swap out several residues to buy stability. Tesamorelin keeps the whole native sequence intact, so the surface the receptor actually sees is unchanged, and protects only the one weak point that needed protecting.

How does it act on cells?

Through the GHRH receptor, usually written GHRHR. It’s a class B G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary, and it couples to Gs.

The chain of events is textbook:

1. Tesamorelin binds GHRHR.
2. Gs activates adenylyl cyclase.
3. Intracellular cAMP rises.
4. Protein kinase A switches on and phosphorylates downstream targets, including the transcription factor CREB.
5. Somatotrophs release stored GH and ramp up GH gene transcription.

Downstream of that, GH drives IGF-1 production, which is why IGF-1 is the usual readout in animal models. In cell systems, people typically measure cAMP directly, or GH secretion if they’re working with pituitary cells.

One point people sometimes miss: GHRH agonists push on the stimulatory side of a system that still has its brakes. Somatostatin keeps inhibiting GH release, and the feedback loops stay in place. That’s a big part of why researchers studying the axis find GHRH analogs interesting in the first place. You’re nudging one input, not overriding the whole circuit.

Where did it come from?

The short history goes like this.

GHRH itself was isolated and sequenced in the early 1980s. Pretty quickly, researchers figured out that the first 29 residues carry most of the biological activity. That observation led to sermorelin, GHRH (1-29)-NH2, which was marketed as Geref for a time and then discontinued in 2008 for commercial reasons.

The shorter fragment still had the same DPP-4 weakness at the N-terminus, though. So a parallel line of work aimed at stabilizing the full-length hormone instead of trimming it. That’s where tesamorelin came from. Theratechnologies developed it, and the pharmaceutical form, sold as Egrifta, was approved by the FDA in 2010 for a specific clinical indication.

Separately from that branded drug, tesamorelin is now widely available to labs as research-grade lyophilized material, usually in 10 mg vials. Same sequence, very different channel and purpose. More on that further down.

If 29 residues are enough, why keep all 44?

Good question, and the answer depends on what you’re trying to learn.

The 1-29 region holds the main determinants for receptor activation. Residues 30 through 44 aren’t required for activity in the way the front end is. So in a pure “does it switch the receptor on” sense, a 29-mer gets you there.

But the native hormone is 44 residues long. If your study is about the endogenous ligand, or you want a stabilized molecule you can compare directly against native GHRH (1-44), keeping the full length removes a variable. You’re testing one change (the N-terminal cap) instead of two (the cap plus a truncation). For clean experimental design, that matters more than people expect.

What do labs actually study with it?

A fairly wide spread of things, as it turns out. The most common categories I come across:

• Receptor pharmacology. Concentration-response curves for cAMP in GHRHR-expressing cell lines, often run side by side with native GHRH and shorter analogs.
• Enzymatic stability. Incubating the peptide with DPP-4 or plasma and tracking the intact fraction over time by HPLC or LC-MS. It’s a nice, clear demonstration of what N-terminal protection does.
• Pituitary cell models. GH secretion from primary pituitary cultures or relevant cell lines, with and without somatostatin present.
• Animal model work. Studies where IGF-1 is the downstream readout of GHRH receptor activation.
• Structure-activity comparisons. Using tesamorelin as a benchmark when testing other acylation strategies or modified sequences.
• Analytical method development. A well-defined peptide of about 5 kDa is a handy test case for HPLC and mass spec methods, including impurity profiling for deletion sequences and oxidation.

Here’s a small scenario that comes up a lot. A grad student wants to show why N-terminal protection matters. They set up three arms (native GHRH, sermorelin, tesamorelin), incubate each with DPP-4, and pull samples at 0, 5, 15, 30 and 60 minutes for HPLC. The native and 1-29 peptides lose their intact peaks fast. The tesamorelin peak hangs on. It’s a two-day experiment and it teaches more about peptide design than a week of reading.

How fragile is it?

In lyophilized form, not very. Dry tesamorelin powder is stable when stored at -20 °C, kept dry, and kept away from light. Short room-temperature transit, like a normal shipping window, is fine.

The real threats are the usual ones for peptides:

• Moisture. Lyophilized peptides pull water from the air. Let a cold vial reach room temperature before opening it, so condensation doesn’t form inside.
• Light. Store vials in a box or opaque bag.
• Temperature cycling. Repeated warm-cold-warm trips through a frost-free freezer aren’t great. Use a manual-defrost freezer if you have one.
• Oxidation. Tesamorelin keeps the native methionine at position 27, which can oxidize over time. On an HPLC trace, oxidized material often shows up as a small, earlier-eluting peak.

Once a peptide is in solution, its stability drops sharply. Solution handling is lab-specific and should follow your own validated procedures, so I won’t go further than that here.

What should the paperwork show?

A certificate of analysis for tesamorelin should give you, at minimum:

• HPLC purity, with the actual chromatogram and the main-peak area percentage
• Identity confirmation, either by mass spec (expect roughly 5,136 Da) or by HPLC retention time against a reference standard
• A lot number that matches the vial in your hand
• A test date
• The name of the testing lab, ideally independent of the seller
• The stated fill or content per vial

If any of those are missing, I’d treat the purity number as decoration.

Where do researchers get it?

From a direct research supplier with published documentation is my strong preference. The one I point people to is HEEZ Research, mostly because they publish the COA on the product page before you buy, which is rarer than it should be.

Their current lot, HZ-1008-TES10-01, tested at 99.84% purity by HPLC, with identity confirmed by HPLC retention time, through an independent accredited third-party lab. The report for the previous lot, HZ-2608-TSM10-01, is still published as well, so you can see consistency across batches rather than one isolated result.

On pricing, HEEZ Research sells a single size, a 10 mg lyophilized vial, at $115 ($11.50 per mg). Bundles bring that down a lot: buy two and get one free (three vials for $230, about $7.67 per mg), or buy three and get two free (five vials for $345, which is $6.90 per mg). There’s also a Research Panel where you pick any four products at 25% off, putting tesamorelin at $86.25 a vial, and a monthly Auto-Ship option for groups with steady use. Orders go out quickly via UPS with tracking.

One more thing I respect: they’re strictly research use only and give no usage guidance. That’s how it should be for material sold for lab work.

Isn’t the research version just the drug?

Same peptide sequence, yes. Same product, no.

Egrifta is a prescription pharmaceutical, formulated and regulated for one approved clinical use, and distributed through medical channels. Research-grade tesamorelin is lyophilized peptide sold for laboratory research only. It isn’t manufactured, labeled or tested to pharmaceutical standards, and it isn’t meant for anything outside the lab. Keep that distinction clear in your records and in how you talk about your work.

The question I wish more people asked

Not “what is tesamorelin?” but “what am I comparing it against?”

A tesamorelin result on its own tells you that a stabilized GHRH agonist did something in your system. Paired with native GHRH (1-44), it tells you what the N-terminal cap contributes. Paired with sermorelin, it tells you something about full length versus the 29-mer. Paired with somatostatin, it tells you how the signal behaves against the brakes. Pick your comparator before you order anything, because it decides how many vials you need, which other peptides go on the order, and which experiment you’re actually running.

Stay updated, free articles. Join our Telegram channel

Join